Testimony Before the FDA’s Pharmacy Compounding Advisory Committee Regarding Adding Lorcaserin Hydrochloride to the List of Drug Products Withdrawn or Removed from the Market

View as PDF

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Pharmacy Compounding Advisory Committee, Public Citizen urged that all drug products containing lorcaserin hydrochloride be added to the list of drugs that have been withdrawn or removed from the market because they were deemed unsafe or not effective and that therefore may not be compounded under the exemptions provided by Section 503A(a) or Section 503B(a) of the Food, Drug, and Cosmetic Act.

View our other work related to pharmacy compounding.